Hikma Pharmaceuticals PLC 2025 AR2
The report highlights Hikma Pharmaceuticals' financial and operational performance in 2025, during which the company achieved a 7% increase in revenue to $3,349 million and launched 84 new products. Key milestones included the launch of Tyzavan, a patent-protected ready-to-use injectable sepsis treatment, and the approval of its first biosimilar product in the US. The company also restructured its R&D function into a unified global organization with three specialized hubs. On the sustainability front, Hikma refreshed its "Acting Responsibly" framework and achieved a 16% reduction in Scope 1 and 2 greenhouse gas emissions compared to its 2020 baseline.
Company: Hikma Pharmaceuticals PLC
Sector: Health Care
Country: United Kingdom
Year: 2025
Type: AR2
Pages: 113
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma Pharmaceuticals' financial and operational performance in 2025, during which the company achieved a 7% increase in revenue to $3,349 million and launched 84 new products. Key milestones included the launch of Tyzavan, a patent-protected ready-to-use injectable sepsis treatment, and the approval of its first biosimilar product in the US. The company also restructured its R&D function into a unified global organization with three specialized hubs. On the sustainability front, Hikma refreshed its "Acting Responsibly" framework and achieved a 16% reduction in Scope 1 and 2 greenhouse gas emissions compared to its 2020 baseline.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Women on Board
Women in Management
Employees